Table 1 Demographic and pathological characteristics and cellular inhibitor of apoptosis protein 1/cellular inhibitor of apoptosis protein 2 expression analysis of the pancreatic ductal adenocarcinoma (PDAC) cases included in the tissue arrays (patients with resectable PDAC).
| Case | Gender | Age (years) | pT | pN | pM | G | cIAP1 | cIAP2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | LN | PanIN | Primary | LN | PanIN | |||||||||
| LG | HG | LG | HG | |||||||||||
| 1 | M | 58 | 3 | 1 | 0 | 1 | Neg | Pos C | ||||||
| 2 | M | 70 | 3 | 1 | 0 | 3 | Pos C | Pos C | Pos C | Pos C | ||||
| 3 | M | 63 | 3 | 1 | 0 | 2 | Pos C | Neg | Neg | Pos C | Neg | |||
| 4 | F | 58 | 3 | 1 | 0 | 2 | Neg | Neg | Neg | Pos C | Neg | |||
| 5 | F | 70 | 3 | 1 | 0 | 2 | Neg | * | ||||||
| 6 | F | 73 | 3 | 1 | 0 | 3 | Pos C | Neg | Pos C | Neg | ||||
| 7 | F | 57 | 3 | 1 | 0 | 2 | Neg | Neg | ||||||
| 8 | M | 65 | 3 | 1 | 0 | 2 | Pos C/N | Pos C/N | ||||||
| 9 | F | 61 | 3 | 1 | 0 | 2 | Pos C | Pos C | Pos N | Pos C | ||||
| 10 | M | 76 | 3 | 1 | 1 (PER) | 2 | Pos N | Pos C | ||||||
| 11 | M | 73 | 3 | 1 | 0 | 3 | Pos C | Pos C | Pos C | Pos C | Pos C | Pos C | Pos C | Pos C |
| 12 | F | 68 | 3 | 1 | 0 | 2 | Pos C | Pos C | Neg | Pos C | Neg | Neg | ||
| 13 | F | 49 | 3 | 1 | 0 | 2 | Neg | Neg | Neg | Pos C | ||||
| 14 | M | 38 | 3 | 0 | 0 | 3 | Pos N | Pos C/N | ||||||
| 15 | F | 66 | 3 | 1 | 1 (LYM) | 2 | Pos C/N | Pos C/N | Neg | |||||
| 16 | M | 65 | 3 | 1 | 0 | 3 | * | Pos C | ||||||
| 17 | M | 73 | 3 | 1 | 0 | 2 | Pos C/N | Pos C/N | Pos C/N | |||||
| 18 | M | 48 | 3 | 1 | 0 | 3 | Pos C | Pos C/N | Pos C | Pos C | ||||
| 19 | M | 60 | 3 | 1 | 0 | 2 | Pos N | Pos C | ||||||
| 20 | M | 75 | 3 | 1 | 0 | 2 | Neg | Neg | ||||||
| 21 | F | 79 | 3 | 1 | 1 (LIV) | 3 | Pos C/N | Pos C | ||||||
| 22 | M | 73 | 3 | 1 | 0 | 2 | Pos C/N | Pos C | Pos C | Pos C | ||||
| 23 | F | 57 | 3 | 1 | 0 | 2 | Pos C | Pos C | Pos C | Pos C | Pos C | Neg | ||
| 24 | M | 60 | 3 | 1 | 0 | 3 | Pos C | Pos C/N | ||||||
| 25 | M | 73 | 3 | 0 | 0 | 3 | Pos C | Pos C | ||||||
| 26 | F | 67 | 3 | 1 | 0 | 3 | Pos C | Pos C | ||||||
| 27 | F | 65 | 3 | 1 | 0 | 2 | Pos C | Pos C | ||||||
| 28 | M | 74 | 3 | 1 | 0 | 1 | Pos C/N | Pos C/N | ||||||
| 29 | M | 71 | 3 | 1 | 0 | 3 | Pos C/N | Pos C/N | ||||||
| 30 | F | 73 | 3 | 1 | 0 | 3 | Pos C/N | Pos C/N | ||||||
| 31 | M | 64 | 3 | 1 | 0 | 2 | Pos C | Pos C | ||||||
| 32 | M | 65 | 3 | 1 | 0 | 2 | Pos C | Neg | ||||||
| 33 | M | 63 | 3 | 1 | 0 | 2 | Pos C | Pos C | ||||||
| 34 | F | 69 | 3 | 1 | 0 | 3 | Pos C | Pos C | ||||||
C, cytoplasmic expression; cIAP1, cellular inhibitor of apoptosis protein 1; cIAP2, cellular inhibitor of apoptosis protein 2; F, female; HG, high grade; LG, low grade; LN, lymph node metastasis; M, male; N, nuclear expression; Neg, negative staining in <10% of the cancer cells; PanIN, pancreatic intraepithelial neoplasia; Pos, positive staining in ⩾10% of the cancer cells.
*Two cases could not be evaluated because of insufficient quality of the tissue on the array.